Table 2.
Reported first-, second-, and third-line treatments for patients with advanced disease.
| Treatments used (not mutually exclusive) | No. (%) of respondents (n = 27) | ||
|---|---|---|---|
| First-line | Second-line | Third-line | |
| SSA | 17 (63%) | 5 (19%) | 2 (7%) |
| CT | 3 (11%) | 9 (33%) | 11 (41%) |
| Surgery | 6 (22%) | — | 1 (4%) |
| mTOR inhibitor/targeted therapy | 1 (4%) | 7 (26%) | 3 (11%) |
| RT | — | 2 (7%) | 1 (4%) |
| PRRT | — | 3 (11%) | 5 (19%) |
| Interferon | — | — | 1 (4%) |
| Clinical trial | — | 1 (4%) | 1 (4%) |
| Not known/not applicable∗ | 3 (11%) | 2 (7%) | 5 (19%) |
∗Respondents who reported that they refer patients to another centre or specialist for treatment. CT: chemotherapy; mTOR: mammalian target of rapamycin; PRRT: peptide receptor radionuclide therapy; RT: radiotherapy; and SSA: somatostatin analogue.